• After the Covid pandemic, we have resumed stem cell treatments. Appropriate sterility and great care in sanitisation is undertaken as usual. If you are unwell with a cough cold or respiratory symptoms it is best to postpone your procedure.

Auto-Immune Diseases Library

Hair follicle stem cell marker nestin expression in regenerating hair follicles of patients with alopecia areata.

150 150 NZ Stem Cell Treatment Centre

Eur J Dermatol. 2011 Mar-Apr;21(2):209-12. Hair follicle stem cell marker nestin expression in regenerating hair follicles of patients with alopecia areata. Amoh Y, Maejima H, Niiyama S, Mii S, Hamada Y, Saito N, Katsuoka K. Source Department of Dermatology, Kitasato University School of Medicine, Sagamihara, Japan. Abstract Cells that are nestin positive and keratin 15…

read more

Involvement of the bulge region with decreased expression of hair follicle stem cell markers in senile female cases of alopecia areata.

150 150 NZ Stem Cell Treatment Centre

J Eur Acad Dermatol Venereol. 2011 Nov;25(11):1346-50. doi: 10.1111/j.1468-3083.2010.03956.x. Epub 2010 Dec 29. Involvement of the bulge region with decreased expression of hair follicle stem cell markers in senile female cases of alopecia areata. Yoshida R, Tanaka K, Amagai M, Ohyama M. Source Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. Abstract BACKGROUND:…

read more

Alopecia Areata

150 150 NZ Stem Cell Treatment Centre

Alopecia Areata is a genetically related auto-immune condition in which the body attacks its own hair follicles resulting in small bald patches. It can involve the entire scalp (totalis) or the entire body (universalis). Sometimes patients spontaneously improve and others continue to worsen. Steroid therapy and topical immune-suppressants are frequently used for treatment. There are…

read more

Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4.

150 150 NZ Stem Cell Treatment Centre

Rheumatol Int. 2010 Jul;30(9):1183-9 Authors: Xu S, Lu H, Lin J, Chen Z, Jiang D Arachidonic acid metabolites, such as leukotriene B4 (LTB4), are known to play an important role in pathogenesis of rheumatoid arthritis (RA). Apart from leukocytes, RA synovial fibroblasts (RASF) produce a broad array of inflammatory mediators to recruit, retain and activate…

read more

Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?

150 150 NZ Stem Cell Treatment Centre

Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):62-8 Authors: D’Arena G, Taylor RP, Cascavilla N, Lindorfer MA Conventional treatment of autoimmune hemolytic anemia (AIHA) comprises corticosteroids and splenectomy and/or other immunosuppressive drugs for refractory/relapsed patients. Monoclonal antibodies (MoAbs) rituximab and alemtuzumab have gained widespread acceptance in the management of B-cell malignancies. More recently, they have…

read more

Bmx regulates LPS-induced IL-6 and VEGF production via mRNA stability in rheumatoid synovial fibroblasts.

150 150 NZ Stem Cell Treatment Centre

Biochem Biophys Res Commun. 2008 Jun 13;370(4):599-602 Authors: Palmer CD, Mutch BE, Page TH, Horwood NJ, Foxwell BM Discordant cytokine production is characteristic of chronic inflammatory conditions like rheumatoid arthritis (RA), and anti-cytokine therapeutics are becoming routinely used to treat RA in the clinic. Fibroblasts from rheumatoid synovium have been shown to contribute to cytokine…

read more

Rheumatoid arthritis and cardiovascular disease.

150 150 NZ Stem Cell Treatment Centre

Curr Atheroscler Rep. 2008 Apr;10(2):128-33 Authors: Dhawan SS, Quyyumi AA Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease affecting approximately 1% of the adult general population. Cardiovascular disease is recognized as the leading cause of death in RA patients, accounting for nearly 40% of their mortality. Patients with RA are at a twofold increased…

read more

Tumor necrosis factor-alpha inhibits chondrogenic differentiation of synovial fibroblasts through p38 mitogen activating protein kinase pathways.

150 150 NZ Stem Cell Treatment Centre

Mod Rheumatol. 2008;18(4):366-78 Authors: Okuma-Yoshioka C, Seto H, Kadono Y, Hikita A, Oshima Y, Kurosawa H, Nakamura K, Tanaka S We previously reported that synovial fibroblast-like cells (SFs) can be differentiated into chondrocytes through activin receptor-like kinase (ALK) 3 activation. The aim of this study was to clarify the effect and signaling pathways of tumor…

read more

Multipotent mesenchymal stromal cells in articular diseases.

150 150 NZ Stem Cell Treatment Centre

Best Pract Res Clin Rheumatol. 2008 Apr;22(2):269-84 Authors: Jorgensen C, Djouad F, Bouffi C, Mrugala D, Noël D Although cartilage defects are common features of osteoarthritis and rheumatoid arthritis, current treatments can rarely restore the full function of native cartilage. Recent studies have provided new perspectives for cartilage engineering using multipotent mesenchymal stromal cells (MSC).…

read more

Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.

150 150 NZ Stem Cell Treatment Centre

Eur J Pharmacol. 2008 Jun 24;588(1):93-8 Authors: Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J A new class of selective cyclooxygenase-2 (COX-2) inhibitors has been identified by high throughput screening. Structurally distinct from previously described selective COX-2 inhibitors, these benzopyrans contain a carboxylic acid function…

read more